Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.82 |
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.82 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.82 |
| ▸ | HTR2A | P28223 | 7/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.82 |
| ▸ | HRH1 | P35367 | 7/20 | 0.82 |
| ▸ | DRD3 | P35462 | 7/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL8911628 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29686418 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL8914157 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29634451 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL718254 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40755 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL1806022 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40756 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL28763049 | 0.95 | LMNA (0.91) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL871706 | 0.92 | MAPT (0.85) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1027892-B1 | Azithromycin combination for emesis control in dogs | PFIZER PROD INC (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | disclosed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| EP-1027892-A2 | Azithromycin combination for emesis control in dogs | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-1014977-A1 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP LIMITED (GB) | 2000-07-05 | — | — | EP | disclosed |
| EP-1014977-A4 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP LTD (GB) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998007426-A1 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP, LTD. (GB) | 1998-02-26 | — | — | WO | disclosed |